Company Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types.
In addition, the company’s products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV).
Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis.
Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
| Country | United Kingdom |
| Founded | 2008 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 493 |
| CEO | Bahija Jallal |
Contact Details
Address: 92 Park Drive, Milton Park Abingdon, OX14 4RY United Kingdom | |
| Phone | 44 12 3543 8600 |
| Website | immunocore.com |
Stock Details
| Ticker Symbol | IMCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $26.00 |
| CIK Code | 0001671927 |
| CUSIP Number | 45258D105 |
| ISIN Number | US45258D1054 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bahija Jallal Ph.D. | Chief Executive Officer and Executive Director |
| Travis A. Coy | Chief Financial Officer, Executive Vice President and Head of Corporate Development |
| Tina St. Leger | Executive Vice President and Chief Human Resources Officer |
| Dr. David Berman M.D., Ph.D. | Executive Vice President of Research and Development |
| John Trainer M.B.A. | SVice President and Chief Operating Officer |
| John Goll III | SVice President, Finance and Chief Accounting Officer |
| Annelise Vuidepot Ph.D. | Senior Vice President, Chief Technology Officer and Research and UK Site Lead |
| Sean D. Buckley | Vice President and Chief Information Officer |
| Clayton Robertson | Head of Investor Relations |
| Lily Margaret Hepworth | Executive Vice President, General Counsel and Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 7, 2025 | 8-K | Current Report |
| May 7, 2025 | 10-Q | Quarterly Report |
| Apr 4, 2025 | ARS | Filing |
| Apr 4, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 24, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 17, 2025 | 144 | Filing |